Stansberry Asset Management, LLC Global Blood Therapeutics, Inc. Transaction History

Stansberry Asset Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 15, 2020	SELL	$41.72 - $87.2 $4.82 Million - $10.1 Million	-115,638 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$45.7 - $81.86 $170,643 - $305,665	-3,734 Reduced 3.13%	115,638 $9.19 Million
Q3 2019 Nov 14, 2019	BUY	$45.35 - $57.91 $218,133 - $278,547	4,810 Added 4.2%	119,372 $5.79 Million
Q2 2019 Aug 14, 2019	SELL	$52.6 - $63.29 $317,283 - $381,765	-6,032 Reduced 5.0%	114,562 $6.03 Million
Q1 2019 May 15, 2019	BUY	$39.99 - $53.48 $1.75 Million - $2.34 Million	43,695 Added 56.82%	120,594 $6.38 Million
Q4 2018 Feb 14, 2019	SELL	$31.54 - $46.67 $242,227 - $358,425	-7,680 Reduced 9.08%	76,899 $3.16 Million
Q3 2018 Nov 14, 2018	SELL	$38.0 - $51.1 $1.3 Million - $1.75 Million	-34,196 Reduced 28.79%	84,579 $3.21 Million
Q2 2018 Aug 14, 2018	BUY	$38.7 - $50.15 $2.61 Million - $3.38 Million	67,363 Added 131.03%	118,775 $5.37 Million
Q1 2018 May 15, 2018	BUY	$39.6 - $65.9 $4,395 - $7,314	111 Added 0.22%	51,412 $2.48 Million
Q4 2017 Feb 12, 2018	BUY	$29.7 - $45.7 $1.52 Million - $2.34 Million	51,301	51,301 $2.02 Million

288K

Ticker GBT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,476,200
Market Cap $4.62B
Description
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses...

Get notified when there are updates to the investment portfolio of Stansberry Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Stansberry Asset Management, LLC with notifications on news.